Search | Clinical Trials Finder

Conditions: Psoriasis
Interventions: Text reminder; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Bladder Cancer, Bladder Tumor, Muscle-Invasive Bladder Cancer
Interventions: Nivolumab, Radical cystectomy (RC), Bempegaldesleukin; Biological · Procedure
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 15
States / cities: Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 12 more

Conditions: Leukemia
Interventions: Lirilumab, Nivolumab, Azacitidine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tumor
Interventions: ipilimumab, nivolumab, ENHANZE (rHuPH20); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Hartford, Connecticut • Fort Wayne, Indiana

Conditions: Healthy Participants
Interventions: Abatacept; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: Cypress, California • Miami, Florida • Las Vegas, Nevada

Conditions: Venous Thrombosis
Interventions: Apixaban, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 2,711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 87
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 82 more

Conditions: Obesity, Overweight, Healthy
Interventions: PF-04620110, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Atrial Fibrillation, Atrial Flutter
Interventions: warfarin, apixaban; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 20,976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 284
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 206 more

Conditions: Metastatic Colorectal Cancer
Interventions: cetuximab, 5-FU, oxaliplatin, leucovorin; Biological · Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 23
States / cities: Loma Linda, California • Orange, California • San Diego, California + 18 more

Conditions: Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis
Interventions: Varicella Zoster Vaccine, Placebo Injection; Biological · Other
Lead sponsor: Kevin Winthrop; Other
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 5
States / cities: Boise, Idaho • Eagan, Minnesota • Clovis, New Mexico + 2 more

Conditions: Systemic Lupus Erythematosus
Interventions: BMS-986165; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 25
States / cities: Birmingham, Alabama • El Cajon, California • Torrance, California + 21 more

Conditions: Non-small Cell Lung Cancer
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: Greg Durm, MD; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 12
States / cities: Chicago, Illinois • Indianapolis, Indiana • Louisville, Kentucky + 8 more

Conditions: Gastric Cancer, Esophageal Cancer
Interventions: oxaliplatin, capecitabine; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1, Kidney Transplantation
Interventions: Belatacept; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Non Small Cell Lung Cancer, Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell, Non Small Cell Lung Cancer Metastatic, NSCLC, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic
Interventions: MILs™ - NSCLC, nivolumab, tadalafil; Biological · Drug
Lead sponsor: WindMIL Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • Tampa, Florida + 7 more

Conditions: Atrial Fibrillation
Interventions: Interrupted apixaban, Uninterrupted apixaban; Drug
Lead sponsor: Baim Institute for Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 19
States / cities: Huntsville, Alabama • Mission Viejo, California • New Haven, Connecticut + 16 more

Conditions: Prostate Cancer
Interventions: Ipilimumab, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 988 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 44
States / cities: Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 39 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: MDX-1342; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 3
States / cities: Boston, Massachusetts • Buffalo, New York • Houston, Texas

Conditions: Prostate Cancer
Interventions: BMS-986218 and Degarelix, Degarelix; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Rheumatoid Arthritis (RA)
Interventions: abatacept, Methotrexate (MTX); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 15
States / cities: Huntsville, Alabama • Mobile, Alabama • Palo Alto, California + 12 more

Conditions: Lung Cancer, Non-small Cell Lung Cancer (NSCLC)
Interventions: Dasatinib - 1A, Afatinib - 1A, Dasatinib - 1B, Afatinib - 1B; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Etoposide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 6
States / cities: San Francisco, California • New York, New York • Rochester, New York + 1 more

Conditions: Refractory Hematologic Cancer
Interventions: Cdc7-inhibitor (BMS-863233); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Miami, Florida • Tampa, Florida • Boston, Massachusetts + 1 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 8 Years to 12 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Deucravacitinib Adherence Study

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants

Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept

Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer

Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients

Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC

Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation

Study of Immunotherapy to Treat Advanced Prostate Cancer

Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)

Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer

Phase IIIB Subcutaneous Abatacept Monotherapy Study

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma

A Study of BMS-863233 in Patients With Hematologic Cancer

Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)